Cheri E. Klein

Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 But Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers

Rosa F. Yeh, Vincent E. Gaver, Kristine B. Patterson et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2006 · 189 citations

The Tablet Formulation of Lopinavir/Ritonavir Provides Similar Bioavailability to the Soft-Gelatin Capsule Formulation With Less Pharmacokinetic Variability and Diminished Food Effect

Cheri E. Klein, Yi‐Lin Chiu, Walid M. Awni et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2007 · 151 citations

Diminished Food Effect, Pharmaceutical Science, Ritonavir Exposures +13

Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women

Juki Ng, Kristof Chwalisż, David C. Carter et al. · The Journal of Clinical Endocrinology & Metabolism · 2017 · 104 citations · Full text

Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide

Cheri E. Klein · Clinical Pharmacology & Therapeutics · 2002 · 79 citations

Recirculatory pharmacokinetic models of markers of blood, extracellular fluid and total body water administered concomitantly.

T C Krejcie, T. K. Henthorn, Carsten Utoft Niemann et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 66 citations